Topotecan is named as an intervention in 31 current clinical trials in our China, USA, UK, Ireland and India registers. 18 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sichuan Baili Pharmaceutical Co., Ltd (3). The most-studied condition is Small Cell Lung Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Small Cell Lung Cancer | 4 |
| Epithelial Ovarian Cancer | 3 |
| Ovarian Cancer | 3 |
| Small Cell Lung Cancer (SCLC) | 2 |
| Neuroblastoma | 2 |
| Platinum-resistant Ovarian Cancer | 2 |
| Retinoblastoma | 2 |
| Fallopian Tube Cancer | 2 |
| Primary Peritoneal Cancer | 2 |
| Ovarian Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Peritoneal Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Neoplasms, Lung | 1 |
| Cervical Cancer | 1 |
| Small Cell Lung Carcinoma (SCLC) | 1 |
| Solid Cancer | 1 |
| Extensive-stage Small-cell Lung Cancer | 1 |
| Small-cell Lung Cancer | 1 |
| Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 |
| Ewing Sarcoma | 1 |
| Solid Tumors | 1 |
| Rhabdoid Tumor | 1 |
| Rhabdomyosarcoma | 1 |
| Large Cell Neuroendocrine Cancer (LCNEC) | 1 |
| Neuroendocrine Prostate Cancer (NEPC) | 1 |
| Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) | 1 |
| Recurrent or Metastatic Cervical Cancer | 1 |
| Retinoblastoma, Recurrent | 1 |
| SCLC | 1 |
| Small Cell Lung Cancer Extensive Stage | 1 |
| Chemotherapy Effect | 1 |
| Relapsed Small Cell Lung Cancer | 1 |
| Endometrial Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 3 |
| Eli Lilly and Company | 2 |
| Daiichi Sankyo | 2 |
| Genmab | 2 |
| Hansoh BioMedical R&D Company | 2 |
| AstraZeneca | 1 |
| Amgen | 1 |
| GlaxoSmithKline | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Boehringer Ingelheim | 1 |
| BioNTech SE | 1 |
| Gilead Sciences | 1 |
| Pfizer | 1 |
| Nerviano Medical Sciences | 1 |
| AbbVie | 1 |
+ 10 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 23 | 14 |
| Clinical trials in USA | 16 | 9 |
| Clinical trials in UK | 11 | 5 |
| Clinical trials in Ireland | 5 | 3 |
| Clinical trials in India | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
31 current trials in our China, USA, UK, Ireland and India registers name Topotecan as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 18 of the 31 trials are recruiting: 14 with sites in China, 9 with sites in USA, 5 with sites in UK, 3 with sites in Ireland and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sichuan Baili Pharmaceutical Co., Ltd (3), Eli Lilly and Company (2), Daiichi Sankyo (2) and Genmab (2), among 25 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Topotecan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Topotecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Topotecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.